FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W152000682> ?p ?o ?g. }

• W152000682 endingPage "72" @default.
• W152000682 startingPage "466" @default.
• W152000682 abstract "The efficacy of chemotherapy for advanced gastric cancer is now widely accepted. However, the survival advantage is small, and no internationally accepted standard regimen has emerged. The present study investigated the efficacy and safety of oxaliplatin plus oral capecitabine (XELOX regimen) as first-line chemotherapy in previously untreated patients with advanced gastric cancer.Patients received intravenous oxaliplatin (130 mg/m2 over 2 h on day 1) plus oral capecitabine (1,000 mg/m2 twice daily on days 1-14). Treatments were repeated every 3 weeks.Seventy-four patients were enrolled in the study, median age was 61 years (range, 32-74); median follow-up was 13.2 months (range, 2-24.5). In total, 364 cycles of chemotherapy were delivered. Overall response rate was 62.2% (95% CI, 51.2-73.2), with 3 complete and 43 partial responses; median time to progression and overall survival were 5.9 (95% CI, 4.8-7.0) and 10.8 months (95% CI, 7.9-13.7), respectively. The most common hematological adverse event was anemia (67.6% of patients). Grade 3-4 neutropenia was observed in 5 patients. The most common nonhematological toxicities were neuropathy (64.9%), nausea/vomiting (48.6%), diarrhea (28.4%), and hand-foot syndrome (39.2%). Grade 3-4 toxicities were rare. There were no treatment-related deaths.The XELOX regimen was active and well-tolerated as first-line chemotherapy in patients with advanced gastric cancer." @default.
• W152000682 created "2016-06-24" @default.
• W152000682 creator A5007965297 @default.
• W152000682 creator A5022282621 @default.
• W152000682 creator A5037377300 @default.
• W152000682 creator A5041786187 @default.
• W152000682 creator A5043358731 @default.
• W152000682 creator A5063344415 @default.
• W152000682 creator A5065131571 @default.
• W152000682 creator A5076110710 @default.
• W152000682 creator A5078046045 @default.
• W152000682 creator A5082610149 @default.
• W152000682 date "2011-10-13" @default.
• W152000682 modified "2023-10-14" @default.
• W152000682 title "Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer." @default.
• W152000682 cites W121414984 @default.
• W152000682 cites W1530403388 @default.
• W152000682 cites W1619192225 @default.
• W152000682 cites W1819328846 @default.
• W152000682 cites W1837926236 @default.
• W152000682 cites W1848862702 @default.
• W152000682 cites W1905936368 @default.
• W152000682 cites W1910716144 @default.
• W152000682 cites W1965734230 @default.
• W152000682 cites W1977569133 @default.
• W152000682 cites W1999562420 @default.
• W152000682 cites W2007093497 @default.
• W152000682 cites W2028794391 @default.
• W152000682 cites W2029409133 @default.
• W152000682 cites W2030395635 @default.
• W152000682 cites W2035185002 @default.
• W152000682 cites W2044970916 @default.
• W152000682 cites W2052457410 @default.
• W152000682 cites W2056634859 @default.
• W152000682 cites W2110415532 @default.
• W152000682 cites W2122879222 @default.
• W152000682 cites W2127773543 @default.
• W152000682 cites W2128328462 @default.
• W152000682 cites W2128403792 @default.
• W152000682 cites W2137194656 @default.
• W152000682 cites W2139248078 @default.
• W152000682 cites W2140663796 @default.
• W152000682 cites W2142751306 @default.
• W152000682 cites W2169106066 @default.
• W152000682 cites W2170884630 @default.
• W152000682 cites W2171232394 @default.
• W152000682 cites W2290882986 @default.
• W152000682 cites W2415936575 @default.
• W152000682 doi "https://doi.org/10.1700/950.10399" @default.
• W152000682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21989435" @default.
• W152000682 hasPublicationYear "2011" @default.
• W152000682 type Work @default.
• W152000682 sameAs 152000682 @default.
• W152000682 citedByCount "4" @default.
• W152000682 countsByYear W1520006822013 @default.
• W152000682 countsByYear W1520006822014 @default.
• W152000682 countsByYear W1520006822016 @default.
• W152000682 crossrefType "journal-article" @default.
• W152000682 hasAuthorship W152000682A5007965297 @default.
• W152000682 hasAuthorship W152000682A5022282621 @default.
• W152000682 hasAuthorship W152000682A5037377300 @default.
• W152000682 hasAuthorship W152000682A5041786187 @default.
• W152000682 hasAuthorship W152000682A5043358731 @default.
• W152000682 hasAuthorship W152000682A5063344415 @default.
• W152000682 hasAuthorship W152000682A5065131571 @default.
• W152000682 hasAuthorship W152000682A5076110710 @default.
• W152000682 hasAuthorship W152000682A5078046045 @default.
• W152000682 hasAuthorship W152000682A5082610149 @default.
• W152000682 hasConcept C121608353 @default.
• W152000682 hasConcept C126322002 @default.
• W152000682 hasConcept C141071460 @default.
• W152000682 hasConcept C143998085 @default.
• W152000682 hasConcept C197934379 @default.
• W152000682 hasConcept C2776694085 @default.
• W152000682 hasConcept C2777063308 @default.
• W152000682 hasConcept C2777909004 @default.
• W152000682 hasConcept C2778248108 @default.
• W152000682 hasConcept C2778336483 @default.
• W152000682 hasConcept C2778496288 @default.
• W152000682 hasConcept C2780580376 @default.
• W152000682 hasConcept C2780852908 @default.
• W152000682 hasConcept C2780962732 @default.
• W152000682 hasConcept C2781413609 @default.
• W152000682 hasConcept C526805850 @default.
• W152000682 hasConcept C71924100 @default.
• W152000682 hasConcept C90924648 @default.
• W152000682 hasConceptScore W152000682C121608353 @default.
• W152000682 hasConceptScore W152000682C126322002 @default.
• W152000682 hasConceptScore W152000682C141071460 @default.
• W152000682 hasConceptScore W152000682C143998085 @default.
• W152000682 hasConceptScore W152000682C197934379 @default.
• W152000682 hasConceptScore W152000682C2776694085 @default.
• W152000682 hasConceptScore W152000682C2777063308 @default.
• W152000682 hasConceptScore W152000682C2777909004 @default.
• W152000682 hasConceptScore W152000682C2778248108 @default.
• W152000682 hasConceptScore W152000682C2778336483 @default.
• W152000682 hasConceptScore W152000682C2778496288 @default.
• W152000682 hasConceptScore W152000682C2780580376 @default.

• next